Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma

Prognosis of patients with pancreatic adenocarcinoma is poor. Many prognostic biomarkers have been tested, but most studies included heterogeneous patients. We aimed to investigate the prognostic and/or predictive values of four relevant biomarkers in a multicentric cohort of patients. A total of 47...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2012-09, Vol.23 (9), p.2327-2335
Hauptverfasser:	Bachet, J.B., Maréchal, R., Demetter, P., Bonnetain, F., Couvelard, A., Svrcek, M., Bardier-Dupas, A., Hammel, P., Sauvanet, A., Louvet, C., Paye, F., Rougier, P., Penna, C., Vaillant, J.C., André, T., Closset, J., Salmon, I., Emile, J.F., Van Laethem, J.L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - metabolism Adenocarcinoma - mortality Adenocarcinoma - secondary Adenocarcinoma - therapy adjuvant chemotherapy Adult Aged Aged, 80 and over Antineoplastic agents Biological and medical sciences Biomarkers, Tumor - metabolism Chemotherapy, Adjuvant CXCR4 Disease Progression Female Gastroenterology. Liver. Pancreas. Abdomen Humans Kaplan-Meier Estimate Liver. Biliary tract. Portal circulation. Exocrine pancreas LKB1 Lymphatic Metastasis Male Medical sciences Middle Aged Multivariate Analysis pancreatic adenocarcinoma Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Pancreatic Neoplasms - therapy Pharmacology. Drug treatments Proportional Hazards Models Prospective Studies Receptors, CXCR4 - metabolism Smad4 Smad4 Protein - metabolism Treatment Outcome Tumors type II TGF-β receptor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!